Navigation Links
MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Date:12/13/2007

VANCOUVER and SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended October 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study being conducted by our development and commercialization partner Cadence Pharmaceuticals is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial. Cadence expects they will complete enrollment of the 1,850 patients planned for the trial in the second quarter of 2008, with results available in the second half of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit a New Drug Application ("NDA") for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II 12-week combination therapy study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

In conjunct
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2008)...RNewswire-USNewswire/ -- MedImmune announced today...ademy of Pediatrics (AAP),2008 National Conference...dy of research into the prevention of respiratory ...spiratory infection among preterm infants., "As w... RSV disease on,preterm babies, the benefits of pr...
(Date:10/10/2008)...., Oct. 10 /- Neurobiologic...oday announced it will hold a,conference call on M...rinex(TM) (ancrod) Phase 3 Trial Program for acute... Freiman, president and chief executive,officer an...-- Date: Monday, October 13, 2008 -- Time: 1:00 ...
(Date:10/10/2008)...exas, Oct. 10 /- CSMG,Techn...ology management,company, announced the company ha...approval is on a key divisional application for "B...Frequency Electric Current,Therethrough" for CSMG ..."),platform tissue bonding/welding technology. The...
(Date:10/10/2008)...f., Oct. 10 /- Finesse Solutions, LLC...ons for life science process,applications, is plea...tore,that makes shopping for sensors and transmitt...inesse web site ( http://www.finesse.com/shopfines... sensors and accessories,on-line, anywhere in the ...
Breaking Biology Technology:MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 2MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 3MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 4MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 5Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
...bout the latest outrages in the CEO suite, let me ...jority of top executives are honest and good peopl... success. And that the CEO,s I will be talking abo...g. Still, these are people who work the system to ... that can easily lead even the most successful com...
... promote competition. It was supposed to create ce... better infrastructure. Ten years later, can we sa...s wasted? Did we ever really achieve the open comp...esday is the tenth anniversary of the act. Especia... these controversies surrounding competition and t...
...d Software, a Milwaukee-based startup that runs an...eships around the universe. , , Official screensh...Technology Innovation Center that houses many more...s like Shining Brow Software and Niceware Inter...t Vendetta Online , came about in part because of...
...ank of Green Bay have joined a new $125 venture fu..., Tonka Bay Equity Partners of Minnetonka, Minnes...s from around the country and some individual inve...sinesses in manufacturing and business services. ,...roughout Wisconsin, but they,re particularly focus...
Other Biology Technology:What color is your CEO's parachute? 2What color is your CEO's parachute? 3What color is your CEO's parachute? 4Was the Telecom Act of 1996 a boon or bomb for U.S.? 2Was the Telecom Act of 1996 a boon or bomb for U.S.? 3Was the Telecom Act of 1996 a boon or bomb for U.S.? 4Was the Telecom Act of 1996 a boon or bomb for U.S.? 5John Bergman, co-founder of Guild Software 2John Bergman, co-founder of Guild Software 3
(Date:10/12/2008)...elease is also available in French . , Resear...and GlaxoSmithKline Inc. have identified two genet... astounding sevenfold increase the risk of male pa...t. 12 in the journal Nature Genetics. , About ...ldness by age 45. The condition,s social and econo...
(Date:10/12/2008)...ave a built-in weapon against HIV, but until recen... study published online by the journal Nature re...me known as APOBEC-3G and suggests new directions... every human cell. It is capable of stopping HIV a...us transcribes its RNA into viral DNA. , The stu...
(Date:10/10/2008)... for Special Surgery researchers have found that s...n who are suffering from pregnancy complications c...g to a study in mice. In this autoimmune syndrome,...ipids, the main components of cell membranes. This...issue of the Journal of Clinical Investigation t...
(Date:10/10/2008)...chers report on a previously unknown relationship ...f their mitochondria a cell,s energy makers. Stem ...eater capacity to differentiate and are more likel...his week in JBC, could lead to methods of enrichin...eutic use and may provide some insights into the r...
Breaking Biology News(10 mins):Researchers discover baldness gene: 1 in 7 men at risk 2Body's anti-HIV drug explained 2Statins may prevent miscarriages 2Statins may prevent miscarriages 3Toms of Maine Tooth Floss Earns American Dental Associations Seal of Acceptance 1187 1Toms of Maine Tooth Floss Earns American Dental Associations Seal of Acceptance 1187 2J D Power and Associates Reports 3A CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year 1184 1J D Power and Associates Reports 3A CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year 1184 2J D Power and Associates Reports 3A CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year 1184 3Verdict One Releases Directory of Board Certified Attorneys for Consumers 1181 1Verdict One Releases Directory of Board Certified Attorneys for Consumers 1181 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion P 562 1Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion P 562 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion P 562 3
...nsion in yeast have been identified by researchers...ically reducing calorie intake, or caloric restric...ncluding yeast, worms and rodents. Previous resear...on due to caloric restriction, but worms and yeast...gh diet, showing that some other genes must be at ...
...s nerve cells to trees -- some are short and bushy...ew branches coming out of one or two main trunks. ...ic disorders and Firestein,s quest is to discover ..., A new paper by Firestein and her colleagues at R...es the role of the protein snapin in nerve branch,...
...have found that gene expression in the brain can d...h different life histories. Their study indicates ...how differential expression in males who migrate f...ns versus those who do not leave the freshwater en... University, the University of Massachusetts and t...
...e biological trigger that gives rise to Van Buchem...that can cause blindness and deafness. The finding...and could lead to new treatments for osteoporosis ...eam from Lawrence Livermore and Lawrence Berkeley ... BioMedical Research in Switzerland, and the DOE J...
Other Biology News:Snapin: A protein with therapy potential for autism 2Divergent life history shapes gene expression in brains of salmon 2Researchers track down cause of a disfiguring bone disorder 2Researchers track down cause of a disfiguring bone disorder 3
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) from Molecular Probes (Invitrogen)
Biotools 2.2 from Bruker Daltonics
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)
Biology Products: